Nowa wersja platformy, zawierająca wyłącznie zasoby pełnotekstowe, jest już dostępna.
Przejdź na


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
2008 | 3 | 2 | 135-140
Tytuł artykułu

The neuroendocrine tumors of the ileum

Treść / Zawartość
Warianty tytułu
Języki publikacji
Neuroendocrine tumors arise from the diffuse neuroendocrine system and secrete several peptides and bioactive amines (serotonin, histamine, dopamine, norepinephrine, corticotropin, calcitonin, bradykinin, kalikrein, gastrin, cholecystokinin, prostaglandins). The most common occurrence site of neuroendocrine tumors is the ileum. The symptoms of small bowel carcinoids are represented by intermittent intestinal obstruction and carcinoid syndrome. Presence of the carcinoid syndrome usually indicates hepatic or retroperitoneal metastases. The typical carcinoid syndrome is characterized by flushing, diarrhea, nonspecific abdominal pain and bronchospasm. The diagnosis of small bowel tumors is often difficult due to their rarity and the nonspecific and variable nature of the presenting signs and symptoms. The most useful initial diagnostic test for the carcinoid syndrome is to measure 24-hour urinary excretion of 5-hydroxyindolacetic acid (5 HIAA), which is the end product of serotonin metabolism. Capsule endoscopy is a more recent diagnostic tool. Surgery is the radical form of curative therapy for carcinoid tumors. Numerous therapies are available for palliation including surgery, pharmacologic therapy, interventional radiologic therapy, embolization and chemoembolization of hepatic metastases, immunotherapy (Interferon alfa) and chemotherapy. We carefully reviewed the available literature on this topic before beginning our study.

Opis fizyczny
  • 2nd Medical Department, University of Medicine and Pharmacy luliu Hatieganu, Cluj, Romania
  • 2nd Medical Department, University of Medicine and Pharmacy luliu Hatieganu, Cluj, Romania,
  • [1] Feldman M., Friedman L.S., Brandt L.J., Gastrointestinal carcinoid tumors and the carcinoid syndrome, Sleisenger & Fordtran’s Gastrointestinal and Liver Disease, 8th ed., 2006
  • [2] Janmohamed S., Bloom S.R., Carcinoid tumours, Postgrad Med J., 1997, 73, 207–214[Crossref]
  • [3] Caplin M.E., Buscombe J.R., Hilson A.J., Jones A.L., Watkinson A.F., Burroughs A.K., Carcinoid tumour, Lancet 1998, 352, 799–805[Crossref]
  • [4] Modlin I.M., Sandor A., An analysis of 8305 cases of carcinoid tumors, Cancer, 1997, 79, 813–829<813::AID-CNCR19>3.0.CO;2-2[Crossref]
  • [5] Timmins P.F., Kuo D.Y., Anderson P.S., Fields A.L., Whitney K.D., Goldberg G.L., Ovarian carcinoid: Management of primary and recurrent tumors, Gynecol Oncol., 2000, 76,112–114[Crossref]
  • [6] Yokoyama Y., Fujioka S., Kato K., Tomono H., Yoshida K., Nimura Y., Primary carcinoid tumor of the gallbladder: Resection of a case metastasizing to the liver and analysis of outcomes, Hepatogastroenterology, 2000, 47, 135–139
  • [7] Chamberlain R.S., Blumgart L.H., Carcinoid tumors of the extrahepatic bile duct: A rare cause of malignant biliary obstruction, Cancer, 1999, 86, 1959–1965<1959::AID-CNCR12>3.0.CO;2-H[Crossref]
  • [8] Fukai I., Masaoka A., Fujii Y., Thymic neuroendocrine tumor (thymic carcinoid): A clinicopathologic study in 15 patients, Ann. Thorac. Surg., 1999, 67, 208–211[Crossref]
  • [9] Glazier D.B., Murphy D.P., Barnard N., Cummings K.B., Weiss R.E., Primary carcinoid tumour of the testis, British Journal of Urology Int., 1999, 83, 153–154
  • [10] Kehagias D., Moulopoulos L., Smirniotis V., Pafiti A., Ispanopoulos S., Vlahos L., Imaging findings in primary carcinoid tumour of the liver with gastrin production, Br. J. Radiol., 1999, 72, 207–209
  • [11] Burke A.P., Thomas R.M., Elsayed A.M., Sobin L.H., Carcinoids of the jejunum and ileum: An immunohistochemical and clinicopathologic study of 167 cases, Cancer, 1997, 79, 1086–1090<1086::AID-CNCR5>3.0.CO;2-E[Crossref]
  • [12] Yang K., Ulich T., Cheng L., Lewin K.J., The neuroendocrine products of intestinal carcinoids: An immunoperoxidase study of 35 carcinoid tumors stained for serotonin and eight polypeptide hormones, Cancer, 1997, 51, 1918–1926<1918::AID-CNCR2820511027>3.0.CO;2-Y[Crossref]
  • [13] Modlin I.M., Kidd M., Latich I., Zikusoka M.N., Shapiro MD., Current status of gastrointestinal carcinoids, Gastroenterology, 2005, 128, 1717–1751[Crossref]
  • [14] Marshall J.B., Bornarchuk G., Carcinoid tumors of the gut, J. Clin. Gastroenterol., 1993, 16, 123–140[Crossref]
  • [15] Feldman J.M., Carcinoid tumor and syndrome, Semin Oncol., 1987, 15, 237–246
  • [16] Ahlman H., Dahlstrom A., Gronstad K., The pentagastrin test in the diagnosis of the carcinoid syndrome: Blockade of gastrointestinal symptoms by ketanserin, Ann. Surg., 1985, 201, 81–86[Crossref]
  • [17] Cwikła J.B., Buscombe J.R., Caplin M.E., Watkinson A.F., Walecki J., Gorczyca-Wiśniewska E., et al., Diagnostic imaging of carcinoid metastases to the abdomen and pelvis, Med. Sci. Monit., 2004, 10 Suppl., 3, 9–16
  • [18] Grahame-Smith D.G., The carcinoid syndrome, William Heineman Medical Books, London, 1972
  • [19] Vaughan D.J., Brunner M.D., Anesthesia for patients with carcinoid syndrome, Int Anesthesiol Clin., 1997, 35, 129–142[Crossref]
  • [20] Onaitis M.W., Kirshbom P.M., Hayward T.Z., Gastrointestinal carcinoids: characterization by site of origin and hormone production, Ann Surg., 2000, 232, 549–561[Crossref]
  • [21] Nehar D., Lombard-Bohas C., Olivieri S., Claustrat B., Chayvialle J.A., Penes M.C., Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours, Clinical Endocrinology,2004, 60, 644–652[Crossref]
  • [22] D’Halluin P.N., Delvaux M., Lapalus M.G., Sacher-Huvelin S., Ben Soussan E., Heyries L., et al., Does the “Suspected Blood Indicator” improve the detection of bleeding lesions by capsule endoscopy? 2005, 61, 243–249
  • [23] Schmidt S., Felley C., Meuwly J.Y., Schnyder P., Denys A., CT enteroclysis: technique and clinical applications, Eur. Radiol., 2006, 16, 648–660[Crossref]
  • [24] Soga J., Early-stage carcinoids of the gastrointestinal tract, Cancer, 2005, 103, 1587–1595[Crossref]
  • [25] Arnold R., Medical treatment of metastasizing carcinoid tumors, World J. Surgery, 1996, 20, 203–207[Crossref]
  • [26] Creutzfeldt W., Carcinoid tumors: Development of our knowledge, World J. Surgery, 1996, 20, 126–131[Crossref]
  • [27] Sokmensuer C., Gedikoglu G., Uzunalimoglu B., Importance of proliferation markers in gastrointestinal carcinoid tumors: a clinicopathologic study, Hepatogastroenterology, 2001, 48, 720–723
  • [28] Loftus J.P., Van Heerden J.A., Surgical management of gastrointestinal carcinoid tumors, Adv. Surgery, 1995, 28, 317–321
  • [29] Rorstad O., Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract, J. Surg. Oncol., 2005, 89, 151–160[Crossref]
Typ dokumentu
Identyfikator YADDA
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.